Cano Health, Inc. CANOQ
0.24
0.00
0.00%
as of 28 Jun
- Market cap
- $6.6M
- P/E
- 0.0×
Follow CANOQ
Growth Flags
show if company had growth for consecutive years
| Older periods | Jun '23 | Sep '23 | Dec '23 | Mar '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.13 | 0.03 | 0.00 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.65) | (1.98) | (0.32) | (0.02) | |
P/B ratio |
1.62 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.45 | 0.34 | (0.01) | (0.04) | |
EV/EBITDA |
0.00 | 0.00 | 0.07 | 0.28 | |
EV/Operating CF |
(12.20) | (7.12) | 0.19 | 0.84 | |
EV/FCF |
(8.91) | (5.96) | 0.16 | 0.76 | |
Quick Ratio |
0.40 | 0.35 | 0.12 | 0.88 | |
Current Ratio |
0.49 | 0.40 | 0.13 | 0.96 | |
Net Debt/EBITDA |
(4.38) | (11.59) | 0.66 | 1.88 | |
Debt/Assets |
57.26% | 83.16% | 5.45% | 0.56% | |
Debt/Equity |
4.15 | (3.89) | (0.10) | (0.01) | |
Asset Turnover |
1.55 | 1.82 | 2.13 | 1.98 | |
Operating CF/Net income |
0.11 | 0.15 | 0.27 | 0.12 | |
Capex/Depreciation |
(0.22) | (0.02) | (0.01) | (0.04) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
12.97% | 10.26% | 12.02% | 13.02% | |
Intangible Assets out of Total Assets |
0.72 | 0.68 | 0.68 | 0.65 | |
Share Based Compensation of Revenue |
0.26% | (0.52%) | 0.12% | 0.58% | |
Graham Net Nets |
(3.42) | (16.86) | (94.83) | (1,780.11) | |
Graham Number |
0.00 | 666.23 | 1,059.04 | 1,286.72 | |
Earnings Yield |
(105.76%) | (778.19%) | (4,906.41%) | (152,302.32%) | |
Free Cash Flow Yield |
(39.16%) | (223.08%) | (1,029.45%) | (16,159.84%) | |
Revenue per Share |
279.18 | 277.95 | 259.99 | 148.94 | |
Operating CF per Share |
(5.64) | (14.01) | (16.12) | (10.63) | |
Capex per Share |
(2.25) | (2.42) | (0.40) | (0.18) | |
Free Cash Flow per Share |
(7.89) | (16.43) | (16.51) | (10.80) | |
Cash per Share |
10.09 | 14.58 | 34.10 | 39.04 | |
Shareholders Equity per Share |
85.85 | (91.38) | (194.26) | (219.61) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
85.85 | (91.38) | (194.26) | (219.61) | |
Free Cash Flow |
(21.67) | (46.58) | (45.48) | (49.64) | |
Working Capital |
(170.60) | (221.21) | (1,232.60) | (11.92) | |
Capital Expenditures |
(6.19) | (6.87) | (1.09) | (0.81) | |
Net Current Asset Value |
(1,305.21) | (1,326.31) | (1,365.92) | (1,799.67) | |
EV/EBIT |
0.00 | 0.00 | 0.02 | 0.12 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(18.36%) | (33.05%) | (23.05%) | (60.74%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
154.08 | 144.77 | 154.81 | 148.22 | |
Average Payables |
97.12 | 123.12 | 107.04 | 87.67 | |
Average Assets |
1,924.36 | 1,704.04 | 1,471.33 | 1,494.96 | |
Average Common Equity |
538.39 | 261.97 | (20.36) | (252.40) |
Columns are period end dates